Hologic, Inc. revised earnings guidance for the Fiscal year 2024. For the year, the Company expects revenues of $3,990 million to $4,065 million compared to previous guidance of $3,920 million to $4,020 million and GAAP EPS of $3.52 to $3.67 compared to previous guidance of $3.19 to $3.39.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
75.86 USD | 0.00% | -0.04% | +6.20% |
02:33pm | Argus Adjusts Price Target on Hologic to $95 From $89 | MT |
05-06 | Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.20% | 17.7B | |
+8.76% | 219B | |
+8.42% | 185B | |
+14.32% | 135B | |
+27.70% | 107B | |
+14.93% | 51.28B | |
+4.48% | 51.01B | |
+4.30% | 41.85B | |
+6.67% | 37.02B | |
+26.00% | 31.27B |
- Stock Market
- Equities
- HOLX Stock
- News Hologic, Inc.
- Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024